



Supplement Figure 1



(A,B) Concentration-response curve in RAW 264.7 cells of two non-selected *Nlrp3*-specific ASO candidates. Cells were treated with the *Nlrp3*-specific ASOs at concentrations ranging from 156 nM to 10 μ M for three days. *Nlrp3* expression is displayed relative to mock-treated cells (set as 1). The mean and SD from three technical replicates are shown.


Supplement Figure 2



(A-C) Bone marrow derived macrophages were cultured from *Nlrp3* knock-in mice and stimulated with 200 ng/mL LPS for 4 hours, with *Nlrp3*-specific ASO or Neg-Ctrl oligonucleotide. (A) *Nlrp3*-specific ASO is effective at reducing IL-1 β secretion with or without second signal stimulation by ATP. (B) Secreted IL-18 measured by ELISA is unchanged by ASO treatment. (C) Cell death measured by LDH release is not reduced by ASO treatment.

Supplement Figure 3

Brain



Representative images of H&E staining of brain parenchyma. For images of meninges (top), bar indicates 50 μM. For vessels (bottom), bar indicates 100 μM, and 50 μM for the zoomed in box. Images are representative of NOMID-CreL mice treated with *Nlrp3*-specific ASO n=8, and NOMID-CreL mice treated with Neg-Ctrl n=7